Tarsus Pharmaceuticals Inc. (TARS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off
TARS has been marketing Xdemvy (lotilaner) aggressively, with Q1'25 seeing advertisement on network TV, moving beyond previous advertising on streaming platforms. TARS can expand lotilaner beyond Demodex blepharitis, with trials set to initiate in H2'25 in ocular rosacea and 2026 for Lyme disease prevention. TARS is guiding for up to a 25% increase in bottles of Xdemvy dispensed in Q2'25, compared to Q1'25, although the company has often beaten its guidance for bottles dispensed.
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants David Nakasone – Head-Investor Relations Bobby Azamian – Chief Executive Officer and Chairman Aziz Mottiwala – Chief Commercial Officer Jeff Farrow – Chief Financial Officer and Chief Strategy Officer Sesha Neervannan – Chief Operating Officer Conference Call Participants Lachlan Hanbury-Brown – William Blair Andrea Newkirk – Goldman Sachs Pavan Patel – Bank of America Eddie Hickman – Guggenheim Cory Jubinville – LifeSci Capital Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to Tarsus First Quarter 2025 Earnings Conference Call.
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $1.01 per share a year ago.
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?
The mean of analysts' price targets for Tarsus Pharmaceuticals (TARS) points to a 31.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tarsus Pharma: Strong Execution In Xdemvy Commercialization
Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts project Tarsus' revenue to reach $352M in 2025, driven by expanding sales, Medicare/Medicaid reimbursement, and increasing consumer awareness. Tarsus' pipeline includes promising candidates TP-04 for Ocular Rosacea and TP-05 for Lyme disease, enhancing long-term growth prospects.
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants David Nakasone - Head of IR Bobby Azamian - CEO and Chairman Aziz Mottiwala - CCO Seshadri Neervannan - COO Jeff Farrow - CFO and CSO Conference Call Participants Francois Brisebois - Oppenheimer Corey Jubinville - Life Sci Capital Jason Gerberry - Bank of America Oren Livnat - HC Wainright Eddie Hickman - Guggenheim Securities Andrea Newkirk - Goldman Sachs Lachlan Hanbury-Brown - William Blair Operator Good morning, and welcome to Tarsus Year End 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $1.31 per share a year ago.
Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet
The consensus price target hints at a 27% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants David Nakasone - Head, IR Bobby Azamian - Chairman & CEO Aziz Mottiwala - Chief Commercial Officer Jeff Farrow - CFO and CSO Sesha Neervannan - COO Elizabeth Yeu - Chief Medical Officer Conference Call Participants Eddie Hickman - Guggenheim Securities Lachlan Hanbury-Brown - William Blair Andrea Newkirk - Goldman Sachs Oren Livnat - HC Wainwright Balaji Prasad - Barclays Jason Gerberry - Bank of America Merrill Lynch Corey Jubinville - Life Sci Capital Francois Brisebois - Oppenheimer Operator Welcome to Tarsus' Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded at this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call.
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago.
